Work

Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)

Year: 2019

Type: article

Source: Prostate Cancer and Prostatic Diseases

DOI: 10.1038/s41391-019-0152-3

Authors: Charles J. Ryan, Sandipan Dutta, William K. Kelly, Carly Russell, Eric J. Small, Michael J. Morris, Mary-Ellen Taplin, Susan Halabi

Institutions: University of Minnesota, Masonic Cancer Center, Duke Medical Center, Thomas Jefferson University, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Harvard University, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: Alliance Statistics and Data Management Center, Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center, Serum Androgens as Predictors of Survival in Metastatic Prostate Cancer, Alliance for Clinical Trials in Oncology Operations Center, Cancer Center Support Grant

OpenAlex ID: W2942595457

FWCI: 1.083

Cites: 15

Cited by: 12

Related to: 10